Drug Type Small molecule drug |
Synonyms Setipiprant (USAN/INN), ACT-129968, KYTH-105 |
Target |
Action antagonists |
Mechanism CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H19FN2O3 |
InChIKeyIHAXLPDVOWLUOS-UHFFFAOYSA-N |
CAS Registry866460-33-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10326 | Setipiprant | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhinitis, Allergic, Seasonal | Phase 3 | United States | - | |
Rhinitis, Allergic, Seasonal | Phase 3 | - | - | |
Androgenetic Alopecia | Phase 2 | United States | 14 Jul 2016 | |
Asthma | Phase 2 | United States | - | |
Asthma | Phase 2 | Australia | - | |
Asthma | Phase 2 | Bulgaria | - | |
Asthma | Phase 2 | Germany | - | |
Asthma | Phase 2 | Hungary | - | |
Asthma | Phase 2 | Israel | - | |
Asthma | Phase 2 | Poland | - |
Phase 2 | 169 | Placebo (Placebo) | muelfmugrj(yqvblljjcd) = jvbghsuwec xghklstkzp (wtlfztnoob, 3.25) View more | - | 05 Apr 2019 | ||
(Setipiprant) | muelfmugrj(yqvblljjcd) = nfjiycxnsm xghklstkzp (wtlfztnoob, 3.03) View more | ||||||
Phase 2/3 | 579 | ylethooeqj(mkfansbgql): difference = -0.15 (95% CI, -0.29 to -0.01), P-Value = 0.030 | Positive | 04 Apr 2017 | |||
Placebo |